Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bayer Aktienges ADR
(OP:
BAYRY
)
7.460
+0.170 (+2.33%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bayer Aktienges ADR
< Previous
1
2
3
4
5
6
Next >
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment
July 17, 2023
Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in...
Via
Benzinga
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
June 29, 2023
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)...
Via
Benzinga
Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study
June 28, 2023
Bayer AG (OTC: BAYRY) (OTC: BAYZF) and its subsidiary BlueRock Therapeutics LP announced
Via
Benzinga
Experimental Stem Cell Therapy For Parkinson's Shows Promise in Phase I Trial: Reuters
June 28, 2023
Via
Benzinga
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender
June 27, 2023
The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday.
Via
Investor's Business Daily
Daily Stock Analysis: Bayer AG - May '23 Update
May 17, 2023
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as over the counter products.
Via
Talk Markets
Bayer: Aspirin To Crop Protection
December 18, 2022
Pharmaceutical drugs account for 41% of Bayer's revenues and include Xarelto, Eylea, Mirena, Kogenate and Nexavar. Its OTC product lineup is filled with household names like Aleve, Alka Seltzer,...
Via
Talk Markets
Unmasking Q2 2023's Stars & Strugglers: Industry ETFs And Top Stock Standouts
June 27, 2023
Via
Benzinga
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
June 23, 2023
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a
Via
Benzinga
There’s Only One Way To Beat The Market
June 12, 2023
The way Wall Street makes money has fundamentally shifted in recent years. So has the way information flows to individual investors. Today, I want to show you how savvy stock pickers can profit from...
Via
Talk Markets
Perrigo Picks Former Bayer Executive As New CEO
June 08, 2023
Perrigo Co PLC (NYSE: PRGO) disclosed the appointment of Patrick Lockwood-Taylor as its new President, CEO and member of the Board of Directors,
Via
Benzinga
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
April 27, 2023
Evogene employs an artificial intelligence platform for decoding plant phenotypes and microbial genomes. Consider its' research agenda, applications, and at-the-market products. The set-up may present...
Via
Talk Markets
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
April 24, 2023
Via
Benzinga
After That Big Merger, What Happened?
April 15, 2023
There are often substantial controversies over whether a merger should be allowed to happen, but then relatively little follow-up after the event.
Via
Talk Markets
InvestorNewsBreaks – ROTH MKM’s Agribusiness Investment Banking Group Serves as Sellside Advisor for Three M&A Transactions
April 11, 2023
Via
Investor Brand Network
Topics
Derivatives
Exposures
Derivatives
Russia Warns As Finland Joins NATO, Spotify Highlights Struggle With Live Audio, Anticompetitive Charges Against Activision Blizzard: Today's Top Stories
April 04, 2023
Benzinga Finland Joins NATO Doubling Border Length, Russia Issues Warning
Via
Benzinga
US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities
April 04, 2023
Via
Benzinga
Evogene Offers An Excellent Risk/Reward Ratio
March 21, 2023
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their...
Via
Talk Markets
Bayer Seeks To Double US Revenues Over Next Decade, With Planned R&D Spending Of Around $1B
March 10, 2023
Bayer AG (OTC: BAYRY) intends to shell out around $1 billion on drug research and development in the U.S. in 2023 as it works to double its sales in the U.S. over the next ten years.
Via
Benzinga
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue
February 15, 2023
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among...
Via
Benzinga
Bayer Snags Ex-Roche Exec Bill Anderson As New CEO; Shares Rocket
February 08, 2023
Bill Anderson, who previously headed up Roche's pharma division, will take over June 1.
Via
Investor's Business Daily
Investors Always Miss This Key Element
January 30, 2023
Return on invested capital, or ROIC, is one of the most critical inputs needed to figure out the value of a company.
Via
Talk Markets
Ring The Register; Plus, Where To Park Your Profits
January 23, 2023
Sometimes an investment works out a lot quicker than expected. That’s the case with my July 2022 pick, Freeport-McMoRan Inc., the fourth-largest copper mining company in the world.
Via
Talk Markets
Bayer Bolsters Its Position In Digital Medical Imaging With Acquisition Of UK-Based Firm
January 18, 2023
Via
Benzinga
FAA Technology Glitch Hits US Flights Operations, Coca-Cola & PepsiCo Under FTC Probe, Rivian Hit By Mass Executive Exodus: Today's Top Stories
January 11, 2023
Reuters
Via
Benzinga
Activist Investor Builds Stake In Bayer, Pushes Breakup
January 11, 2023
Activist investor Bluebell Capital Partners has built a stake in Bayer AG (OTC: BAYRY) (OTC: BAYZF) and is pushing it to split up.
Via
Benzinga
Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down
December 19, 2022
MJBiz CEO To Step Down Marijuana Business Daily's Chris Walsh will step down as CEO in January.
Via
Benzinga
Current Report: Bayer AG
November 17, 2022
By my dogcatcher ideal, this may be a prime time to buy Bayer AG shares based on their dividends for the coming year 2022-23.
Via
Talk Markets
Ionis Regains Rights To Thrombosis Candidate From Bayer
November 04, 2022
Via
Benzinga
Can Acquisitions and Partnerships Take Ginkgo Bioworks (DNA) Stock Higher?
October 20, 2022
It seems that Ginkgo Bioworks is announcing a new acquisition or collaboration every day this month, putting DNA stock in focus.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.